We propose to continue the extraordinarily successful Global Alliance in Pharmacogenomics- Japan (GAP-J) as a network resource for the Pharmacogenomics Research Network (PGRN). GAP-J (see Figure XII.1) is an existing alliance (see http://vwvw.nigms.nih.gov/lnitiatives/PGRN/GAP/) between the PGRN and the Center for Genomic Medicine (CGM) of the Riken, Yokohama Institute in Japan (see www.src.riken.ip/english/for description of CGM). This international alliance brings together scientists in multiple research disciplines to conduct research in pharmacogenomics. In particular, the research focuses on genomewide association studies to identify genetic predictors of therapeutic and adverse reactions to medicines. GAP-J was started after initial discussions between Dr. Yusuke Nakamura, Director of the CGM and Drs. Mark Ratain and Kathy Giacomini, Principal Investigators in the PGRN. The discussions centered on the need to expedite discoveries in pharmacogenomics so that personalized medicines could be realized. A partnership between the PGRN, which would contribute rich sets of well-phenotyped samples and the CGM, which would contribute powerful high throughput genomewide methods, was discussed. Formal launching of GAP-J occurred in the Spring of 2008 with a letter of intent signed by Dr. Yusuke Nakamura, Director of the Center for Genome Medicine, Riken;Dr. Scott Weiss, Chair, Pharmacogenefics Research Network;and NIH Institute Directors, Drs. Jeremy Berg (National Institute of General Medical Sciences), John Niederhuber (National Cancer Institute) and Elizabeth Nabel (National Heart, Lung and Blood Institute). Currently fourteen research collaborations focused on genomewide association analysis of many drug response phenotypes are underway in GAP-J (see Table XII.1).

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19GM061390-15
Application #
8689086
Study Section
Special Emphasis Panel (ZRG1-GGG-M)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
$722,061
Indirect Cost
$165,254
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Yee, S W; Giacomini, M M; Hsueh, C-H et al. (2016) Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1. Clin Pharmacol Ther 100:524-536
Zhou, Kaixin; Yee, Sook Wah; Seiser, Eric L et al. (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48:1055-9
Zheng, Yi; Chen, Xijing; Benet, Leslie Z (2016) Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. Clin Pharmacokinet 55:143-67
Benet, Leslie Z; Hosey, Chelsea M; Ursu, Oleg et al. (2016) BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev 101:89-98
Rotroff, Daniel M; Oki, Noffisat O; Liang, Xiaomin et al. (2016) Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. Front Pharmacol 7:135
Yee, S W; Momozawa, Y; Kamatani, Y et al. (2016) Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration. Clin Pharmacol Ther 100:423-426
Li, M; Seiser, E L; Baldwin, R M et al. (2016) ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J :
Eclov, Rachel J; Kim, Mee J; Smith, Robin P et al. (2016) In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus. Drug Metab Dispos :
Hibma, Jennifer E; Zur, Arik A; Castro, Richard A et al. (2016) The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. Clin Pharmacokinet 55:711-21
Yuan, Bo; Yoshino, Yuta; Fukushima, Hisayo et al. (2016) Multidrug resistance-associated protein 4 is a determinant of arsenite resistance. Oncol Rep 35:147-54

Showing the most recent 10 out of 129 publications